KYORIN Holdings, Inc. (4569.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
KYORIN Holdings, Inc.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1982
First IPO Date
January 04, 2001
Key Executives
| Name | Title | Pay | Year Born |
| Yutaka Ogihara | President, Chief Executive Officer & Chairman | 0 | 1967 |
| Kenichi Nakamura | Managing Exec. Officer, CMO & President of KYORIN Pharma Grp Fac Co., Ltd. | 0 | N/A |
| Noriaki Tamura | Managing Exe. Officer, Chief Commercial Officer, GM of Pharma Sales Division & Director | 0 | 1966 |
| Kiyoo Uehara | Managing Executive Officer, CHRO & General Affairs Manager | 0 | N/A |
| Junichi Ishiyama | Managing Executive Officer, CSO & Head of Drug Discovery Div. | 0 | N/A |
| Yasuji Kurose | CFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director | 0 | 1970 |
| Takaaki Kaji | Senior Managing Executive Officer & Chief Business Development Officer | 0 | N/A |
Description
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
